Intrapulmonary solitary fibrous tumor: clinicopathological analysis of 29 cases with emphasis on morphological spectrum and immunohistochemical profile.
Xin Zeng, Xiaodong Lin, Lifang Ye, Zhenyong Wu, Zeyun Lin, Shuting Li
{"title":"Intrapulmonary solitary fibrous tumor: clinicopathological analysis of 29 cases with emphasis on morphological spectrum and immunohistochemical profile.","authors":"Xin Zeng, Xiaodong Lin, Lifang Ye, Zhenyong Wu, Zeyun Lin, Shuting Li","doi":"10.1186/s13000-026-01800-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intrapulmonary solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can mimic pulmonary adenofibroma (PAF) when respiratory epithelium is entrapped.</p><p><strong>Methods: </strong>We retrospectively analyzed 29 intrapulmonary SFTs, reviewing clinical, histopathological, and immunohistochemical features. STAT6, CD34, ER, and PR were evaluated.</p><p><strong>Results: </strong>The cohort included 18 males and 11 females (mean age 55.3 years); 69.0% were asymptomatic. Mean tumor size was 4.11 cm, with pleural attachment in 62.1%. Histologically, 79.3% showed biphasic cellularity, 86.2% had staghorn vessels, and 44.8% exhibited entrapped epithelium. Stromal changes included collagenization (89.7%), hemorrhage (24.1%), myxoid change (20.7%), cystic change (6.9%), and multinucleated giant cells (3.4%). Risk stratification identified 25 low-risk, three intermediate-risk, and one high-risk case. STAT6 was positive in all tested cases (28/28, 100%), and CD34 in 96.3%. Among 22 evaluable cases, 19 (86.4%) showed ER < PR. During a mean follow-up of 36.7 months, one high-risk patient (3.4%) developed local recurrence.</p><p><strong>Conclusion: </strong>Intrapulmonary SFT has a broad morphological spectrum with frequent epithelial entrapment as a key diagnostic pitfall. STAT6 is a reliable diagnostic marker, while ER < PR is common but of uncertain significance.</p>","PeriodicalId":11237,"journal":{"name":"Diagnostic Pathology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591934/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13000-026-01800-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intrapulmonary solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can mimic pulmonary adenofibroma (PAF) when respiratory epithelium is entrapped.
Methods: We retrospectively analyzed 29 intrapulmonary SFTs, reviewing clinical, histopathological, and immunohistochemical features. STAT6, CD34, ER, and PR were evaluated.
Results: The cohort included 18 males and 11 females (mean age 55.3 years); 69.0% were asymptomatic. Mean tumor size was 4.11 cm, with pleural attachment in 62.1%. Histologically, 79.3% showed biphasic cellularity, 86.2% had staghorn vessels, and 44.8% exhibited entrapped epithelium. Stromal changes included collagenization (89.7%), hemorrhage (24.1%), myxoid change (20.7%), cystic change (6.9%), and multinucleated giant cells (3.4%). Risk stratification identified 25 low-risk, three intermediate-risk, and one high-risk case. STAT6 was positive in all tested cases (28/28, 100%), and CD34 in 96.3%. Among 22 evaluable cases, 19 (86.4%) showed ER < PR. During a mean follow-up of 36.7 months, one high-risk patient (3.4%) developed local recurrence.
Conclusion: Intrapulmonary SFT has a broad morphological spectrum with frequent epithelial entrapment as a key diagnostic pitfall. STAT6 is a reliable diagnostic marker, while ER < PR is common but of uncertain significance.
期刊介绍:
Diagnostic Pathology is an open access, peer-reviewed, online journal that considers research in surgical and clinical pathology, immunology, and biology, with a special focus on cutting-edge approaches in diagnostic pathology and tissue-based therapy. The journal covers all aspects of surgical pathology, including classic diagnostic pathology, prognosis-related diagnosis (tumor stages, prognosis markers, such as MIB-percentage, hormone receptors, etc.), and therapy-related findings. The journal also focuses on the technological aspects of pathology, including molecular biology techniques, morphometry aspects (stereology, DNA analysis, syntactic structure analysis), communication aspects (telecommunication, virtual microscopy, virtual pathology institutions, etc.), and electronic education and quality assurance (for example interactive publication, on-line references with automated updating, etc.).